Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.28% | 9.55% | 19.27% | 16.98% | 16.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.28% | 9.55% | 19.27% | 16.98% | 16.62% |
| Cost of Revenue | -3.24% | 5.64% | 7.83% | 6.11% | -1.10% |
| Gross Profit | -7.87% | 11.78% | 26.02% | 23.47% | 28.66% |
| SG&A Expenses | 3.00% | 13.66% | 8.21% | 7.90% | 3.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -97.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.39% | 9.72% | 6.53% | 4.55% | -1.44% |
| Operating Income | -34.52% | 8.58% | 123.40% | 130.10% | 421.68% |
| Income Before Tax | -27.71% | 22.81% | 234.85% | 249.01% | 746.39% |
| Income Tax Expenses | -105.88% | -17.65% | 5.88% | -76.47% | 0.00% |
| Earnings from Continuing Operations | -27.53% | 22.95% | 236.32% | 251.46% | 734.95% |
| Earnings from Discontinued Operations | -61.08% | -48.15% | 26.27% | 21.29% | 65.87% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.91% | 21.91% | 274.38% | 294.73% | 515.44% |
| EBIT | -34.52% | 8.58% | 123.40% | 130.10% | 421.68% |
| EBITDA | -32.01% | 7.21% | 98.61% | 88.80% | 199.08% |
| EPS Basic | -37.36% | 10.70% | 250.09% | 265.88% | 506.89% |
| Normalized Basic EPS | -28.55% | 21.44% | 229.80% | 242.87% | 787.10% |
| EPS Diluted | -100.23% | -67.25% | 96.60% | 155.53% | 503.14% |
| Normalized Diluted EPS | -97.69% | -63.42% | 77.98% | 129.85% | 783.98% |
| Average Basic Shares Outstanding | 1.17% | 1.42% | 1.53% | 1.61% | 1.53% |
| Average Diluted Shares Outstanding | 524.26% | 394.58% | 396.87% | 264.13% | 1.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |